Broad clinical adoption of Chimeric Antigen Receptor (CAR) T cell therapies has been hindered by the complexity, cost, and toxicity of ex vivo manufacturing. Those factors are driving a shift toward in vivo CAR engineering using technologies like lipid nanoparticles (LNPs). However, efficient in vivo targeting remains challenging as LNPs generally accumulate in the liver/spleen, leading to modest transfection rates. Conjugating targeting proteins or antibodies to the surface of LNPs is one way to address this problem. And the single-molecule NanoAnalyzer technology from NanoFCM makes detecting and characterizing the particles in the payload—a necessary quality control step—a routine job.

In this GEN webinar, Joseph Brealey, an expert in nanoparticle delivery, will discuss current strategies for improving quality control of in vivo CAR T therapies. During the webinar, he will describe how NanoFCM’s single-molecule NanoAnalyzer sizes and counts LNPs label-free while detecting mRNA loading ratio, encapsulated mRNA, and surface-bound ligands/antibodies. You will learn how measurements such as mRNA copy number per particle, encapsulation efficiency, and antibody/ligand decoration levels can improve in vivo CAR T conversion efficiency.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.

Produced with support from: